Accudial Pharmaceutical, Inc. Signs Distribution Agreement with BroadMed

Share Article

South Florida Pharmaceutical Leader Expands Distribution to the Middle East and North Africa

AccuDial Pharmaceutical, Inc

“Children’s AccuDial® is the only medication that provides a patented weight-based dosing solution on the bottle label that addresses the need to properly dose our children.” - Khalil Afsh, M.D.

Past News Releases

RSS

Accudial Pharmaceutical, Inc. and BroadMed S.A.L, with headquarters in Lebanon signed an agreement for BroadMed to distribute Children’s AccuDial® analgesic, allergy, cough and cold medications that have been approved by Health Canada. BroadMed anticipates distribution of the AccuDial® brand products in twenty countries in the Middle East and North Africa (“MENA”).

“The demand for quality over-the-counter medication crosses all boarders and AccuDial’s® weight-based dosing is the most accurate way to calculate and administer those medications,” said Robert Terwilliger, Chairman and CEO of Accudial Pharmaceutical, Inc. “This opens up a market that is 50% larger than the United States. The population of these two regions is approximately 459 million people with approximately 142 million being children. That’s more than twice the number of children in the United States.”

“BroadMed is very happy to be able to offer Children’s AccuDial® directly to our wholesalers and retailers,” adds BroadMed’s Chairman and General Manager Khalil Afsh, M.D. “Children’s AccuDial® is the only medication that provides a patented weight-based dosing solution on the bottle label that addresses the need to properly dose our children.”

The distribution agreement is an exclusive agreement for countries of the MENA region. Both companies are looking forward to broadening the reach of administering weight-based dosing to children. Children’s AccuDial® features a revolutionary, two-part, patented label system. A parent or caregiver rotates the label until their child’s weight appears in the viewing window. Below the child’s weight is the proper amount of medication. A caregiver then pours the liquid into the calibrated dosing device (included in the package) to the exact measurement, and the child receives the correct dose of medication. No second guessing; it’s all medical science.

About Accudial Pharmaceutical, Inc.
Accudial Pharmaceutical, Inc. is positioned to change the way liquid medications will be dosed globally. It is the only brand with a patented rotating weight-based dosing system designed to administer over-the-counter medications safely and effectively. Children’s AccuDial® is a family of eight analgesic, allergy, cough and cold pediatric medications available in more than 4,300 pharmacies and stores throughout Canada. Children’s AccuDial® was recognized as the 2011 Product of the Year Canada in consumer drug packaging, and voted “consumer’s choice” for new product innovation. For more information, visit http://productoftheyear.ca/. In April, 2011 Children’s AccuDial® also won Edison Award in the Consumer Packaged Goods category. For more information, visit http://edisonawards.com/. For up to date information about AccuDial, follow us on Facebook at http://www.facebook.com/AccuDialPharmaceutical and Twitter at http://www.twitter.com/AccuDial.

In the United States: AccuDial® will launch Children’s Pain & Fever with acetaminophen in five flavors: cherry, dye-free cherry, bubblegum, strawberry, and grape. All five Pain & Fever medications feature AccuDial®’s weight-based dosing and are expected to be available online by September 2011 on Accuratedose.com, Amazon.com, and a number of leading internet drugstore sites. For more information about AccuDial®, visit accuratedose.com or call 561.429.6886.

About BroadMed s.a.l. and BroadMed International Offshore
BroadMed specializes in registration, sales and marketing of both innovative healthcare products, as well as high quality generic products in select therapeutic areas, to the rapidly growing emerging markets of MENA – Middle East and North Africa regions. BroadMed’s focus is on the commercialization of high-value products for diseases with sharply rising regional incidence and prevalence such as diabetes, obesity, cardiovascular and oncologic diseases, as well as underserved areas like CNS disorders. The BroadMed team is well connected to a wide range of partners in the region, and offers flexible approach to partnership.

The information contained in this press release includes “forward-looking statements.” All statements other than statements of historical facts included in this press release, including the company’s prospects, plans, financial position, and business strategy, may constitute forward-looking statements. These statements are based on the beliefs and assumptions of our management and on the information currently available to our management at the time of such statements. Forward-looking statements generally can be identified by the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” or similar expressions that indicate future events and trends. Although the company believes that the expectations reflected in these forward-looking statements are reasonable, the company can give no assurance that these expectations will prove to be correct, and the company’s actual results may differ significantly from the results discussed in these forward-looking statements. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events, or otherwise.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Steve Young

Terri M. Wescott
Visit website